Epigral Ltd

Epigral Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Epigral Ltd

₹ 1,829 -0.25%
02 Jul 12:46 p.m.
meghmanifinechem.com BSE: 543332 NSE: EPIGRAL
About

Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.

In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.

Key Points

Product Segments
a. Derivatives & Speciality Chemicals (56% in H1 FY25 vs 25% in FY22): [1] [2] The company is the 5th largest producer of Chloromethanes (CMS) in India, its CMS portfolio includes MDC, Chloroform and CTC. It is also 3rd largest producer of Hydrogen Peroxide in India. [3] It also produces specialty chemicals like CPVC Resin, CPVC compound, Epichlorohydrin, Chlorotoluenes Value Chain, etc. [4]

Website BSE NSE
  • Market Cap ₹ 7,890 Cr.
  • Current Price ₹ 1,829
  • High / Low ₹ 2,408 / 1,387
  • Stock P/E 22.4
  • Book Value ₹ 441
  • Dividend Yield 0.32 %
  • ROCE 24.9 %
  • ROE 22.3 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is expected to give good quarter
  • Company has a good return on equity (ROE) track record: 3 Years ROE 24.8%

Cons

  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Part of BSE SmallCap BSE Allcap BSE Commodities Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
499 533 556 538 562 455 478 472 525 651 626 645 628
324 345 375 371 407 360 370 349 369 475 448 463 454
Operating Profit 175 187 180 167 155 95 108 123 155 176 178 183 173
OPM % 35% 35% 32% 31% 28% 21% 23% 26% 30% 27% 28% 28% 28%
2 2 2 -0 5 2 1 2 2 2 6 4 3
Interest 12 11 14 21 19 18 21 20 14 14 27 -0 12
Depreciation 21 22 26 31 30 31 32 31 30 33 32 33 34
Profit before tax 144 156 142 114 110 48 56 74 113 131 124 154 131
Tax % 31% 31% 35% 33% 30% 33% 32% 34% 32% 34% 35% 33% 34%
99 108 92 77 77 32 38 49 77 86 81 104 87
EPS in Rs 23.85 25.94 22.04 18.58 18.48 7.62 9.18 11.87 18.45 20.70 19.38 24.00 20.08
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
394 392 598 710 611 829 1,551 2,188 1,929 2,550
245 248 346 405 416 567 1,041 1,499 1,448 1,839
Operating Profit 149 144 252 306 194 261 510 689 481 711
OPM % 38% 37% 42% 43% 32% 32% 33% 31% 25% 28%
2 1 8 16 2 2 4 8 6 15
Interest 19 14 9 25 11 29 44 66 73 53
Depreciation 44 55 55 54 44 74 86 109 124 133
Profit before tax 88 75 195 242 141 161 383 523 291 540
Tax % 23% 11% 20% 25% 21% 37% 34% 32% 33% 34%
67 67 155 183 112 101 253 353 196 357
EPS in Rs 9.49 9.40 21.97 44.38 27.19 24.48 60.84 85.04 47.12 82.68
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 6% 11% 7%
Compounded Sales Growth
10 Years: %
5 Years: 33%
3 Years: 18%
TTM: 32%
Compounded Profit Growth
10 Years: %
5 Years: 26%
3 Years: 12%
TTM: 80%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 12%
1 Year: 21%
Return on Equity
10 Years: %
5 Years: 27%
3 Years: 25%
Last Year: 22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 71 71 71 41 42 42 42 42 42 43
Reserves 224 291 447 241 331 432 684 1,028 1,213 1,860
190 123 74 601 737 753 993 879 964 593
55 42 79 162 164 223 405 484 576 655
Total Liabilities 540 527 671 1,044 1,273 1,449 2,124 2,432 2,794 3,151
364 398 347 295 440 1,102 1,068 1,804 1,767 2,238
CWIP 69 3 79 468 691 126 589 158 483 64
Investments 0 29 71 0 0 0 0 21 21 97
106 98 173 281 142 221 467 449 524 752
Total Assets 540 527 671 1,044 1,273 1,449 2,124 2,432 2,794 3,151

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
165 229 284 626 398 441
-363 -197 -455 -437 -401 -262
69 -32 195 -200 -8 -164
Net Cash Flow -129 1 24 -11 -11 15

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 43 41 47 40 46 52 60 28 34 33
Inventory Days 75 59 45 58 64 51 74 69 90 105
Days Payable 31 37 51 52 62 69 42 36 63 50
Cash Conversion Cycle 86 63 42 46 48 34 92 61 61 88
Working Capital Days 43 40 19 -26 -65 -59 26 15 25 46
ROCE % 18% 37% 36% 15% 16% 29% 32% 17% 25%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
71.11% 71.12% 71.21% 71.34% 71.37% 71.38% 71.38% 71.49% 71.58% 71.58% 68.94% 68.95%
1.38% 1.40% 1.15% 1.20% 1.16% 1.14% 1.17% 1.36% 1.46% 2.10% 3.01% 3.01%
0.22% 0.19% 0.17% 0.03% 0.04% 0.04% 0.05% 0.02% 0.18% 1.17% 4.31% 4.66%
0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02%
27.27% 27.26% 27.44% 27.39% 27.39% 27.40% 27.37% 27.10% 26.75% 25.12% 23.71% 23.34%
No. of Shareholders 93,14797,39697,01694,77895,83395,74292,95988,87085,76183,17681,69780,878

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls